Nonprofit foundations spur translational research.

Area of Science:

• Pharmacological research
• Neurodegenerative disease therapeutics
• Drug discovery and development

Background:

• Numerous basic discoveries in pharmacology fail clinical translation annually.
• Neurodegenerative disorders, such as Alzheimer's and Parkinson's, lack effective disease-modifying treatments.
• The transition from laboratory findings to patient-ready drugs is a major hurdle in pharmaceutical research.

Purpose of the Study:

• To outline the current challenges in the clinical translation of pharmacological discoveries.
• To propose a novel 'collective-impact' multistakeholder strategy.
• To expedite the development of urgently needed drugs for neurodegenerative diseases.

Main Methods:

• Analysis of current drug development and clinical translation barriers.
• Conceptualization of a collaborative, multistakeholder framework.
• Literature review on successful and unsuccessful drug development initiatives.

Main Results:

• Identification of key bottlenecks hindering the translation of basic research into clinical therapies.
• A proposed model for a 'collective-impact' approach integrating diverse stakeholders.
• Highlighting the potential of collaborative efforts to overcome translational gaps.

Conclusions:

• The current drug development pipeline is inefficient, particularly for neurodegenerative diseases.
• A coordinated, multistakeholder 'collective-impact' model can significantly improve clinical translation rates.
• This approach offers a promising pathway to accelerate the delivery of novel therapies to patients suffering from neurodegenerative disorders.